
‘I'm 26 and slowly dying. In 10 days I'll find out if the NHS can give me a life-saving wonder drug'
Xenpozyme is saving patients' lives in 22 countries around the world. But not Monachan's. The drug has been rejected for approval for use on the NHS, and in a little over a week's time the window for renegotiation closes for good. For Monachan and other patients like her, that is tantamount to a death sentence.
'It's gut-wrenching, it's heartbreaking, that I don't get the treatment just because I live in the UK,' Monachan tells me when I visit her in Belfast. 'There is one other person in Northern Ireland [with Niemann-Pick disease] who has the treatment on compassionate grounds. Why does she get it and not me? If I want a fulfilling life, I need it. It can get your symptoms back to normal. I just want to be normal.'
Monachan's doctor had applied for compassionate use, where patients with serious or life-threatening conditions are given drugs not yet approved for general use when no other suitable treatment options are available, but the request was denied.
Monachan is the loser in a cruel drug lottery. Soon after her diagnosis, the National Institute for Health and Care Excellence (NICE) announced it would not approve Xenpozyme for use on the NHS as it is too expensive. Despite lobbying from NPUK, the only UK charity dedicated to the condition, the NHS, NICE and Sanofi – the pharmaceutical company that developed the drug – have shown no flexibility on price, meaning that negotiations are at a stalemate. Toni Mathieson, the chief executive of NPUK, explains: 'NICE have indicated that there is still a window for negotiation… but the deadline is 10 days away on August 1. If nothing changes, the window to secure access will then close indefinitely.'
That's why NPUK is desperately trying to change the tides on this devastating decision, led by Mathieson, who herself has lost three children to the disease. Earlier this month, Mathieson attended the All-Party Parliamentary Group on rare, genetic and undiagnosed conditions in Parliament. Her mission was to lobby MPs to signal to Sanofi that the NHS is willing to go back to the negotiating table. The charity has urged people to write to their local MP, to Wes Streeting, the Health Secretary, and to Paul Hudson, Sanofi's chief executive. With the final deadline fast approaching, Monachan and her family are losing hope.
We are speaking at the kitchen table in Monachan's flat-share, while her mother, Moya, joins on the phone from Germany. Despite living in different countries, it's clear they are close. 'When she got her diagnosis, I said, 'You were Caitlin yesterday, and the only difference is you're Caitlin today with an answer, which is always a good thing,'' Moya says. 'We had the encouragement of knowing that there was a treatment that's curative.' Finding out that it wasn't available for Monachan, however, was like a 'gut punch'.
For as long as she can remember, Monachan has suffered a range of debilitating and seemingly random symptoms. Growing up in southern England, she had persistent migraines, fatigue and insomnia, and broke so many bones she was jokingly nicknamed 'Calamity Caitlin' by her family. She bled excessively from minor injuries. 'I bleed a lot because I don't tend to clot,' she says. 'So I'm on my period for 20 days of the month, which is hard.' She is small, but so is her mother, so her parents didn't think anything of it. An optician once noticed that she had a cherry-red spot on her retina – another telltale sign of Niemann-Pick – but it is so rare that no one connected the signs.
It was when the family moved to Munich for her father Andrew's job in the automotive industry, in 2014, and got private health insurance that a doctor discovered other unusual symptoms during a routine medical examination: high cholesterol and an enlarged spleen. Monachan was prescribed statins, and after finishing school, moved to Belfast to be near extended family while she completed a college course in professional cookery. A part-time job at a restaurant chain followed, but Monachan continued to struggle with overwhelming fatigue and bone pain. 'When I come home from work, I have to soak my feet in the bath for an hour because my bones get so sore,' she says. She cannot socialise like other people her age, or work full time.
The reason for this remained a medical mystery until she was referred to Dr Paul Hamilton, a consultant chemical pathologist in Belfast who runs a specialist clinic for lipid disorders. 'He asked, 'Have you ever heard of Niemann-Pick disease?'' Monachan says. 'I was just like, no. And he explained that it's a disease that affects the fat breakdown in your body because you don't have a particular enzyme.'
'Looking at Caitlin now, you'd think she was fine,' Moya says of her daughter. 'But that's how she is now, that's not her future. Caitlin has no guarantee of life expectancy. There's no guarantee she will stay this way – the build-up in her organs will impact her life more and more.'
Xenpozyme stops this build-up in its tracks by replacing the enzyme – acid sphingomyelinase – that is deficient in patients with Niemann-Pick disease. The drug has been in development since the late 1990s, and in such a small community of patients – around 36 people in the UK have Monachan's subtype of the condition – many of that number were actively involved with clinical trials in some way. It is so rare, in fact, that every sufferer in the UK – or their parents or caregivers – can gather for an annual conference run by NPUK. Monachan attended in April this year. 'I got to meet so many other people with the same condition,' she says. 'Unfortunately for me, most of them are actually on treatment on compassionate grounds. That was really frustrating to hear.' There is no guarantee, however, that their treatment can continue.
To say that the medicine is expensive is something of an understatement. NPUK estimates that giving 36 patients access to Xenpozyme would cost the NHS £20m a year – about 0.01 per cent of the total NHS budget. The charity says it does not know the cost per patient, but NICE guidelines for the condition state that the medication costs £3,612 per 20mg vial, excluding VAT. It is administered through fortnightly infusions at a recommended dose of 3mg for each kilogram of body weight, so, based on these figures, each treatment would cost nearly £38,000 for a person who weighed 70kg. However, for such a small group of patients, the charity still believes the drug could be affordable if Sanofi, the French pharmaceutical company that produces it, and the NHS could be persuaded to go back to the table.
'We aren't allowed to be involved in the negotiation on cost, but based on the information that we have, we believe that it will cost £20 million a year,' says Mathieson. She describes this as a 'small amount to save people's lives'. She adds, 'I really feel there is no point in developing a drug if the people who it's meant for can't access it. Surely there has to be an answer or an arrangement that can be reached?'
Mathieson's eldest daughter, Lucy, was diagnosed with a severe form of Niemann-Pick at five weeks old. 'She didn't meet any milestones. She never walked. By the age of two, she could crawl a little bit, but by the age of two and a half, she'd lost all of those skills. And from then, we were on a bit of a slippery slope to the end, really.' In that time, devastatingly, Mathieson and her husband had two more children who died shortly after birth from Niemann-Pick. Lucy defied doctors' predictions of her life expectancy and survived for two more years, but died aged four.
'As a mum, the only thing that brought me hope was the hope of a treatment or a therapy that was just around the corner,' Mathieson says. 'Of course, our patients and families have lived with that hope – and now they're being left with no choice but 'best supportive care', which means visiting hospitals a lot and experiencing increasingly challenging symptoms that are progressive and severe and will lead to an early death.'
When contacted, a NICE spokesman said: 'We were disappointed not to be able to recommend olipudase alfa [the medical name for Xenpozyme], and we realise the decision was disappointing for people with Niemann-Pick disease and those who care for them. Unfortunately, both the company's and the independent external advisory group's cost-effectiveness estimates compared with standard care were over £300,000 per quality-adjusted life-year gained.
'So even when taking into account the substantial effect of olipudase alfa on quality and length of life, the cost-effectiveness estimates are higher than what NICE usually considers an acceptable use of NHS resources for highly specialised technologies.'
Francesca Buzer, an Essex-based mother of two boys, has seen the difference the drug can make first hand. Her son Dexter was just one when he became ill. 'As a baby, he was completely fine, and then when he was about one, I started to notice that he had a really bloated belly,' she says. 'I thought he had some kind of food allergy.' When his stomach got so large he was struggling to eat, Buzer took him to the doctors.
'That August, when he was about one and a half, I had him seen, and they said he had an absolutely giant liver and had to go straight to hospital.' Dexter's liver and spleen were so big they stretched from his chest to his groin. 'I thought he would die,' Buzer says. 'It was a very traumatic, scary time.' The local hospital didn't know what was wrong, so they were transferred to King's College Hospital in London to see a liver specialist, and then to Evelina London Children's Hospital.
'They told us that he had Niemann-Pick disease, that it's extremely rare, and that at that point there was nothing available to help him,' Buzer says. 'Everything fell apart. However, there was a drug that's compassionate-use only, and they would have to put a case together for Dexter and wait for that. He was accepted in March 2023, and it changed his life overnight.'
Within three months, he had bounced back to being like any other boisterous, energetic four-year-old. He was able to attend pre-school for the first time (before the medication, he wasn't allowed to go because of the risk of infection). 'He's such a friendly little laddie, very cheeky and confident. It's been amazing,' Buzer says. 'I don't know what else to say – it's been completely life-changing.'
Dexter's access to the treatment is secured despite NICE's decision not to approve it for us on the NHS. But that has done nothing to assuage Buzer's worries about it being stopped in the future. 'That's scary – really, really scary,' she says. 'There's always a what if. What if it stops? They could stop it at any point if they don't want to pay out for it anymore.' That's what it boils down to, for her, for Monachan, and for everyone affected by this cruel disease: the value of their life being calculated in monetary value. It's now the final countdown. Will they be saved?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
28 minutes ago
- The Independent
Graham Thorpe missed mental health appointments before death, inquest told
Former England cricketer Graham Thorpe told a healthcare professional he 'didn't see the point of being here' and missed a number of appointments in the months before he died, an inquest has heard. The 55-year-old died on the morning of August 4 2024 after being struck by a train at a railway station in Surrey. His widow Amanda Thorpe said he had taken his own life. An inquest at Surrey Coroner's Court in Woking heard he had 'spiralled into depression' after losing his job as a batting coach in 2022, and he had tried to take his own life on another occasion. In the weeks leading up to his death, he had asked his wife 'to help him end his life', the court was told. On Thursday, consultant psychiatrist Dr Amirthalingam Baheerathan was asked whether Mr Thorpe's comments required an immediate review, but he said they felt he 'wasn't under imminent risk'. He added that when patients miss appointments with the community mental health team, further attempts would be made to book sessions, with the possibility of virtual appointments or home visits. In Mr Thorpe's case, the situation fluctuated with some appointments attended and others missed, he said. After missing an appointment on June 28 2024, care co-ordinator Katie Johnson spoke to Mr Thorpe. He told her he 'hadn't been out for a while' and 'didn't see the point of being here', but had no immediate plans to act on suicidal thoughts, Dr Baheerathan said in his statement. Mark McGhee, for Mr Thorpe's family, asked if he accepted people who are depressed may not say what they actually mean. Dr Baheerathan said: 'Not all the time. But there are times when in Mr Thorpe's case he said that he will come for the appointments and he came for some of the appointments.' He said the cricketer had agreed to come for follow-up appointments. The last time Dr Baheerathan saw Mr Thorpe was 19 weeks before he died on March 20, 2024, Mr McGhee said. Dr Baheerathan first met with Mr Thorpe in October 2022, after he had been transferred to the community mental health recovery services in August following his discharge from a private hospital. Mr Thorpe had been diagnosed with moderate depressive disorder, Dr Baheerathan told the court, adding his depression was 'fluctuating' and that at some points he was severely depressed. During a meeting in April 2023, Mr Thorpe mentioned he was having 'active suicidal thoughts', which was addressed by making sure he was accompanied when he went to appointments, the psychiatrist said. The inquest previously heard that while on tour in Australia, there was an 'incident involving a video that was taken that had adverse publicity'. Mr Thorpe shared a video with some friends which was leaked, and the incident was 'blown out of all proportion', leaving Mr Thorpe 'distraught', Mrs Thorpe said. According to reports at the time, the video, filmed after a dismal Ashes series which England lost 4-0, showed Tasmanian police breaking up a drinking session involving both England and Australia players. Mrs Thorpe described it as a 'horrible' time, and said the later termination of his employment with the England and Wales Cricket Board was a 'real shock to Graham', which was the 'start of the decline of his mental health'. Mr Thorpe was a mainstay in the England set-up for many years, first as a batter between 1993 and 2005 before spending 12 years in coaching roles. During a distinguished international career, he struck 16 Test hundreds for England, including a debut century against Australia at Trent Bridge in 1993, and represented his country 182 times in all formats. The inquest continues.


The Independent
28 minutes ago
- The Independent
‘Imbalance' of women doctors harming NHS, retired surgeon says
A prominent retired surgeon, Dr Meirion Thomas, has claimed that too many women are pursuing medical degrees, which is detrimental to the NHS. Dr Thomas said that 'women have got to have children', and their subsequent part-time work arrangements negatively impact NHS services, including patient access to GPs. He suggested that medical schools should reduce the intake of female students from the current 60-70 per cent, which is a 'huge imbalance', to a 50-50 gender split. The comments were made amidst ongoing discussions about NHS strikes, with thousands of resident doctors set to walk out for five days. NHS England has urged the public to continue seeking care during the strikes, advising the use of 111 online for urgent but non-life-threatening issues. Patients struggling to get GP appointments because too many women are doctors, retired surgeon claims


BBC News
28 minutes ago
- BBC News
Strike will impact 60,000 London appointments, NHS says
Approximately 60,000 appointments across London will be impacted by a five-day doctors' strike starting on Friday, the medical director for NHS London has said. The British Medical Association (BMA) strike follows a pay dispute with the government over resident doctors - the new name for junior London said cancer and heart surgeries were being prioritised, however care which was not life saving was being "put on the back burner", a move which was "causing distress" and "some harm as well".The BMA said resident doctors had not had a "credible" pay deal for 2025-26, but Health Secretary Wes Streeting argued the strike was "unreasonable" after substantial pay rises in recent years. 'Cumulative effect' Dr Chris Streather, medical director for NHS London, hospitals had "quite a lot of practice" with managing care during industrial action."We will do as much as we can," he said. "But some things will get cancelled inevitably."He added: "The more worrying thing this time around is the cumulative effect of repeated cancellations of planned care."Since 2022 when this all started, we've cancelled nearly 1.5m planned appointments, and every time this happens, we loose about another 60,000."Although we make emergency care safe, we can't really deal with that backlog in planned care." The five-day walkout, which will take place across England, comes after a period of greater demand at St George's, Epsom and St Helier 1 June and 14 July this year, approximately 800 more people attended the hospitals' emergency departments compared with the same period last year, the group of those were admitted to hospital with issues including respiratory problems, shortness of breath, chest pain and falls. Dr Jane Evans, consultant at St George's Hospital in Tooting, said the hospital would have to "try and achieve balance" by managing emergency care and planned appointments during the strike."It's a square peg, round hole situation. We try to do everything, but it's impossible." The BMA said wages were still around 20% lower in real terms than in 2008 and called for "pay restoration".Streeting has made clear there would be no extra pay this year. Dr Melissa Reddy, co-chair of the BMA resident doctors committee, said: "Our door is always open for Mr Streeting to come forth with an offer. "None of us want to go out on strike. I'm a paediatric doctor, I work with children and families and I'd much rather be at work, but we simply need Mr Streeting to act and present us with a credible offer." Dr Streather said the strike would have more of an impact in the capital, where approximately half of doctors were resident doctors. "I and other people are disappointed that resident doctors are striking," he said."The public finances are in a mess and we've got a backlog of patients to deal with, and there isn't money to increase their pay."This can't be about pay... but there's lots of other stuff we can do to improve their working lives and I think we need to take that seriously." The NHS urged people to use its 111 online service, visit a pharmacy for advice or contact their GP where possible. Anyone in need of emergency care should continue to use A&E departments. The strikes take place from 07:00 on Friday until 07:00 on Wednesday.